MilliporeSigma, a Life Science and High Technology company, has extended its ongoing collaboration with Baylor College of Medicine, it was reported on Wednesday.
The collaboration has been extended to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase one clinical trials.
The partnership is intended to improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016. The companies will also develop a new manufacturing platform for a second Covid-19 vaccine candidate to reduce the time to enter into Phase one clinical trials. The aim of the partnership is to develop a suitable manufacturing process and steps that lead to a scale-up approach suitable for pilot and later industrial production.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study